Literature DB >> 19427616

Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Sandeep Grover1, Ravi K Murthy, Vikram S Brar, Kakarla V Chalam.   

Abstract

PURPOSE: To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease.
DESIGN: Prospective, observational study in an academic institutional setting.
METHODS: Fifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance.
RESULTS: Overall, the mean CPT was 227.3 +/- 23.2 microm, and mean CSF was 270.2 +/- 22.5 microm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean +/- standard deviation, 339.5 +/- 16.9 microm). The RT did not show significant difference with age (P = .62) or with gender (P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects (P = .007) in the present study.
CONCLUSIONS: Normative values for macular thickness in otherwise healthy eyes were measured to be 227.3 microm (CPT) and 270.2 microm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 microm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA).

Entities:  

Mesh:

Year:  2009        PMID: 19427616     DOI: 10.1016/j.ajo.2009.03.006

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  112 in total

1.  Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.

Authors:  Paul S Tlucek; James C Folk; Jason A Orien; Edwin M Stone; Vinit B Mahajan
Journal:  Arch Ophthalmol       Date:  2012-11

2.  Change in subfoveal choroidal thickness after argon laser panretinal photocoagulation.

Authors:  Ga Eun Cho; Hee Yun Cho; Yun Taek Kim
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

3.  Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography.

Authors:  Tetsuya Agawa; Masahiro Miura; Yasuhi Ikuno; Shuichi Makita; Tapio Fabritius; Takuya Iwasaki; Hiroshi Goto; Kohji Nishida; Yoshiaki Yasuno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-05-10       Impact factor: 3.117

4.  Interchangeability of macular thickness measurements between different volumetric protocols of Spectralis optical coherence tomography in normal eyes.

Authors:  Yaroslava Wenner; Stephan Wismann; Melanie Jäger; Jörn Pons-Kühnemann; Birgit Lorenz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-20       Impact factor: 3.117

5.  Comparing central retinal thickness in diabetic macular edema measured by two different spectral-domain optical coherence tomography devices.

Authors:  Kiyoshi Suzuma; Yoshihisa Yamada; Michi Liu; Eiko Tsuiki; Azusa Fujikawa; Takashi Kitaoka
Journal:  Jpn J Ophthalmol       Date:  2011-09-03       Impact factor: 2.447

6.  Effect of vitreomacular separation on macular thickness determined by spectral-domain optical coherence tomography.

Authors:  Kazuyuki Kumagai; Akinori Uemura; Masanori Hangai; Tetsuyuki Suetsugu; Nobuchika Ogino
Journal:  Jpn J Ophthalmol       Date:  2016-10-07       Impact factor: 2.447

7.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

8.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-07       Impact factor: 3.117

9.  Novel mutations in MERTK associated with childhood onset rod-cone dystrophy.

Authors:  Donna S Mackay; Robert H Henderson; Panagiotis I Sergouniotis; Zheng Li; Phillip Moradi; Graham E Holder; Naushin Waseem; Shomi S Bhattacharya; Mohammed A Aldahmesh; Fowzan S Alkuraya; Brian Meyer; Andrew R Webster; Anthony T Moore
Journal:  Mol Vis       Date:  2010-03-09       Impact factor: 2.367

10.  Macular thickness measurements in healthy Norwegian volunteers: an optical coherence tomography study.

Authors:  Alexandra Wexler; Trond Sand; Tor B Elsås
Journal:  BMC Ophthalmol       Date:  2010-05-13       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.